Citations

Clear

2 citation(s) found for "Stopczynski, Tess".

Six-Month Outcomes in Children With COVID-19 or Multisystem Inflammatory Syndrome in Children
Howard, Leigh M. , Calvert, Alexis, Stopczynski, Tess , Klintworth, Steven R., Soslow, Jonathan H., Spieker, A, Hilmes, Melissa A. , Dalal, Aarti S., Ruth, Natasha, Mahle, William T. , Schneider, James, Michaels, Marian G., Acker, Karen P. , Danziger-Isakov, Lara, Gans, H, Orr, William B. , Choueiter, Nadine , Kantor, Paul F., Chandani, Harsha K., Chakraborty, Rana, Narula, Pramod, Rossano, Joseph, Singh, Rakesh K. , Trachtman, Rebecca, Pascual, Virginia , Martinez, Olivia M. , Diamond, Betty, Sanz, Ignacio, Boss, Jeremy M., Goldmuntz, E, Morrison, Yvonne, Welch, Beverly, Halasa, Natasha , Webber, Steven A. , Diamond, Betty , Dalal, Aarti , Wilkinson, James D. , Soslow, Jonathan H. , Spieker, Andrew J. , Moore, Paul E. , Ruth, Natasha M. , Michaels, Marian G , Danziger‐Isakov, Lara , Kelly, Matthew S. , Kantor, Paul Fraser , Chandnani, Harsha K., Chakraborty, Rana , Rossano, Joseph, Arditi, Moshe , Trachtman, Rebecca A. , Krams, Sheri M. , Sanz, Igñacio , Boss, Jeremy M. , Bridges, Nancy D. , Goldmuntz, Ellen

Mayo Clinic

Hospital Pediatrics | May 14, 2026 | Volume: 16 | Issue: 6 | Pages: 525-535

10.1542/hpeds.2025-008765 | PMID 42128419 Get It

OBJECTIVES We aimed to characterize the frequency of major complications of acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C) and adolescents present at 6 months after initial presentation. METHODS The Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM) study was a prospective cohort at 20 US pediatric academic medical centers. Individuals aged younger than 21 years meeting any of the following were enrolled: SARS-CoV-2 detection within 7 days, Centers for Disease Control and Prevention (CDC) MIS-C criteria, or CDC MIS-C criteria except having involvement of 1 organ system. The study was designed to assess the proportion of children with major complications (cardiovascular, pulmonary, gastrointestinal/hepatic, renal, and/or neurologic) 6 months after presentation. RESULTS Data were analyzed on 229 hospitalized participants: 59 with COVID-19 (mean age 10.4 years; SD, 5.5) and 170 with MIS-C (mean age 10.1 years; SD, 4.8). Overall, 42.8% were female, making up 55.9% and 38.2% of the COVID-19 and MIS-C groups, respectively. Overall, the frequencies of major complications at 6 months after initial presentation were: 16/195 (8.2%) cardiovascular, 11/154 (7.1%) pulmonary, 11/154 (7.1%) gastrointestinal/hepatic, 3/152 (2.0%) renal, and 3/189 (1.6%) neurologic. Organ system complications did not differ significantly between the COVID-19 and MIS-C groups. Six of 14 (42.9%) COVID-19 and 21/26 (80.7%) MIS-C participants with at least 1 six-month complication had no underlying medical condition that may have been associated with their complication(s). CONCLUSIONS Major complications were infrequent but observed in children without underlying medical conditions, underscoring the importance of prospective follow-up to optimize management and elucidate the complications associated with severe SARS-CoV-2 infection in children.
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
Moyo, Tamara K. , Kishtagari, Ashwin , Villaume, Matthew T. , McMahon, Brandon , Mohan, Sanjay , Stopczynski, Tess , Chen, Sheau‐Chiann , Fan, Run , Huo, Yuankai , Moon, Hyeonsoo , Tang, Yucheng , Bejan, Cosmin A. , Anderson, Ingrid , Rawling, Kyle , Simons, Rhea M. , Moncrief, Ashley , Caza, Rebekah , Dugger, Laura , Collins, Aunshka , Dudley, Channing V. , Byrne, Michael , Ayers, Gregory D. , Mason, Emily F. , Palmer, Jeanne , Michaelis, Laura C. , Mohan, Sanjay R , Childress, Merrida , Anderson, Ingrid , Rawling, Kyle , Simons, Rhea M , Moncrief, Ashley , Caza, Rebekah , Dugger, Laura , Collins, Aunshka , Dudley, Channing V , Ferrell, P Brent , Byrne, Michael , Strickland, Stephen Anthony , Ayers, Gregory D , Landman, Bennett A , Mason, Emily F , Mesa, Ruben , Palmer, Jeanne M , Michaelis, Laura C , Savona, Michael R , Chen, Sheau-Chiann , Kishtagari, Ashwin , Mesa, Ruben A. , Savona, Michael R.

Mayo Clinic

Clinical Cancer Research | April 10, 2023 | Volume: 29 | Issue: 13 | Pages: 2375-2384

10.1158/1078-0432.ccr-22-3192 | PMID 37036505 Get It

Abstract Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferation and induce apoptosis of JAK2V617F-mutant cell lines. Patients and Methods: In a phase I dose-escalation and -expansion study, we evaluated the safety and efficacy of a selective PI3Kδ inhibitor, umbralisib, in combination with ruxolitinib in patients with MF who had a suboptimal response or lost response to ruxolitinib. Enrolled subjects were required to be on a stable dose of ruxolitinib for ≥8 weeks and continue that MTD at study enrollment. The recommended dose of umbralisib in combination with ruxolitinib was determined using a modified 3+3 dose-escalation design. Safety, pharmacokinetics, and efficacy outcomes were evaluated, and spleen size was measured with a novel automated digital atlas. Results: Thirty-seven patients with MF (median age, 67 years) with prior exposure to ruxolitinib were enrolled. A total of 2 patients treated with 800 mg umbralisib experienced reversible grade 3 asymptomatic pancreatic enzyme elevation, but no dose-limiting toxicities were seen at lower umbralisib doses. Two patients (5%) achieved a durable complete response, and 12 patients (32%) met the International Working Group-Myeloproliferative Neoplasms Research and Treatment response criteria of clinical improvement. With a median follow-up of 50.3 months for censored patients, overall survival was greater than 70% after 3 years of follow-up. Conclusions: Adding umbralisib to ruxolitinib in patients was well tolerated and may resensitize patients with MF to ruxolitinib without unacceptable rates of adverse events seen with earlier generation PI3Kδ inhibitors. Randomized trials testing umbralisib in the treatment of MF should be pursued.